{"id":482865,"date":"2021-04-27T16:38:28","date_gmt":"2021-04-27T20:38:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-to-present-pre-clinical-data-at-american-society-of-gene-cell-therapy-annual-meeting-2021\/"},"modified":"2021-04-27T16:38:28","modified_gmt":"2021-04-27T20:38:28","slug":"sana-biotechnology-to-present-pre-clinical-data-at-american-society-of-gene-cell-therapy-annual-meeting-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sana-biotechnology-to-present-pre-clinical-data-at-american-society-of-gene-cell-therapy-annual-meeting-2021\/","title":{"rendered":"Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021"},"content":{"rendered":"
\n

\n \u2014 Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes \u2014<\/em>\n <\/p>\n

SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced\u00a0data from its fusogen technology platform, which are being presented at the virtual American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2021.<\/p>\n

The data to be presented demonstrate in vivo<\/em> gene delivery to T cells and hepatocytes using a re-targetable fusogen delivery method. Sana is developing fusogens as a platform technology to enable the delivery of genetic payloads to specific cell types. Fusogens can bind to cell-surface proteins on the target cell type and then deliver the genetic payload directly to the cell\u2019s cytoplasm. The reliable and efficient delivery of genetic payloads to specific cell types is considered a key obstacle in achieving safe and effective in vivo <\/em>gene modification.<\/p>\n

\u201cThese early data are encouraging by showing that our fusogen platform can not only target specific and varying cell types but also demonstrate tumor cell killing and eradication both in vitro <\/em>and in vivo<\/em>,\u201d said Sunil Agarwal, Sana\u2019s Head of Development and Chief Medical Officer. \u201cThe potential for fusogens to target and deliver therapies to CD4 T cells, CD8 T cells, and hepatocytes in vivo<\/em> highlights the scope of our technologies beyond a single cell type or disease. Though preliminary, developing optimized fusogens represents an important step toward increasing gene therapy options for patients with various cancers and genetic diseases.\u201d<\/p>\n

Data on the fusogen platform were outlined in the abstract for the poster presentation and made available to the public online today. The full poster will be available to ASGCT conference participants beginning Tuesday, May 11 at 6:00 a.m. Eastern Time.<\/p>\n

\n
\n In vivo<\/em>
\n <\/strong>
\n gene delivery to T cells and hepatocytes achieved through a re-targetable fusogen platform<\/strong>
\n
Authors: Jagesh Shah, PhD, et al.<\/p>\n

Key takeaways include:<\/p>\n